Myocardial Metabolic Flux in Pulmonary Arterial Hypertension

计划入组 32 人 · 首次发布于 2026 年 7 月 30 日

Understanding Acute Dietary Changes After GLP-1 Agonist Treatment: The GLaD Feasibility Study

计划入组 40 人 · 首次发布于 2025 年 6 月 3 日

Impact GLP-1 Agonists Following Bariatric

计划入组 150 人 · 首次发布于 2023 年 11 月 15 日

GLP-1 agonist (obesity)

OBM-P01

CYRS-MD01

Alturas Minerals Corp

United States

NHI-1

United States

Xi'an No.1 Hospital

China

Novo Nordisk Enters Agreement with Ascendis Pharma for Monthly GLP-1 Agonist

Nxera Pharma Launches Comprehensive Obesity Pipeline with Novel Oral GLP-1 Agonist

Vincentage Pharma's Oral GLP-1 Agonist VCT220 Achieves 12% Weight Loss in Pivotal Phase 3 Trial